INTRODUCTION
Mental illness is an increasingly common problem across all countries, with depression predicted to come second only to cardiovascular disease as a cause of morbidity by 2020. 1 In response to evidence that depression is often under-detected and under-treated, there have been a number of initiatives since the 1990s to improve diagnosis and treatment. 2, 3 At least partly as a result, the volume of antidepressant prescribing has increased dramatically in developed countries over the last 20 years. [4] [5] [6] In Scotland, prescribing volume quadrupled between 1993-1994 and 2005-2006 from 18 to 85 defined daily doses (DDDs -a standard measure of prescribing volume 7 ) per 1000 population, 4 similar to changes observed in England 5 and the US. 6 In the UK, this has led to concern that antidepressants are being overused, 8, 9 with policy makers setting targets to stabilise or reduce antidepressant prescribing. 10 Possible reasons for the large increase in prescribing volume include the availability of new drugs, changing diagnostic criteria and patient expectations, previous policy that sought to increase detection and treatment of depression, and poor availability of non-pharmacological treatments. [11] [12] [13] [14] Additionally, it is important to recognise that antidepressant drugs are used for a wide range of conditions beyond depression, both because diagnostic categories in mental illness and psychological distress are blurred, and because of expansion of treatment to new indications. 15 Understanding antidepressant prescribing therefore requires more than examining the management of formally diagnosed depression.
Two studies have examined changing patterns of antidepressant prescribing in the UK. The first examined Scottish population-level data and concluded that rising rates of prescribing were not associated with increased incidence or prevalence of mental illness, increased identification of depression, or increased care-seeking behaviour. 16 The second examined longitudinal trends in prescribing for patients with first-ever episodes of depression, using the General Practice Research Database. 17 It concluded that no more patients were being diagnosed with depression, and that the increased volume of prescribing of antidepressants for patients in the cohort was predominately due to increasing numbers receiving longterm treatment. This study gives valuable insight into changing treatment patterns in patients with first-ever episodes of depression, but patients being prescribed antidepressants for recurrent or chronic depression, or for other indications, were excluded.
The aim of this study was to use a patient-level antidepressant prescribing dataset for a complete population, to examine changes in antidepressant volume, the proportion of patients prescribed antidepressants, the duration of antidepressant use, and the dose of antidepressants prescribed.
Aim
To examine time trends in GP antidepressant prescribing using patient-level data.
Design and setting
Longitudinal population database of all community pharmacy dispensed prescriptions for all 325 000 residents of the Tayside region of Scotland.
Method
In each of 3 study years (1995/1996, 2000/2001 and 2006/2007) , the volume of antidepressants prescribed was calculated, and numbers of patients prescribed antidepressants in each year, mean treatment duration, and mean dose per patient in that year examined using descriptive statistics.
Results
Total drug volume increased threefold between 1995/1996 and 2006/2007, largely driven by increases in selective serotonin reuptake inhibitor (SSRI) prescribing, and laterally also in 'other' antidepressant prescribing. Tricyclic prescribing is static, but low-dose amitriptyline increasingly dominates this drug class. Increased drug volume was initially driven by increasing patient numbers (from 8.0% of the population prescribed at least once in 1995/1996 to 11.9% in 2000/2001) and increased treatment duration (from 170 days in the measurement year to 200). Latterly, drug volume increases are increasingly attributable to longer duration of treatment and higher mean daily dose.
Conclusion
The large rise in antidepressant volumes is caused by a complex mixture of more patients being prescribed SSRI and 'other' antidepressants, the use of higher doses, and longer durations of treatment, with the balance changing over time. Tricyclic prescribing is now largely low dose, and probably for conditions other than depression. Interventions to improve the quality of antidepressant prescribing need to be more subtle than blanket targets to reduce the total volume of antidepressants prescribed. 7 Total DDDs dispensed per patient in each of the 3 years examined were calculated. The 'in-year' treatment duration was calculated by summing individual prescriptions' treatment lengths, with an assumed duration of the final prescription in a series of 30 days. Prescriptions before and after the year being examined were used to ensure that 'in-year' treatment duration was correctly estimated for patients on long-term treatment. Mean DDDs per patient in the entire year, and mean DDDs per 28 days of treatment in each year were calculated.
METHOD
Crude and age-sex-standardised percentages of patients prescribed any antidepressant were calculated, and variation in the percentage prescribed an antidepressant examined by age, sex, and socioeconomic deprivation. Prescribing rates were additionally calculated for the three main drug classes (SSRI, TCAD and
How this fits in
Prescribing of antidepressants has increased significantly in many countries, despite little evidence of an associated increased incidence or prevalence of mental illness, increased detection of depression, or increased care-seeking behaviour. This study shows that over the period 1995/1996 to 2006/2007, the increase was initially driven by a combination of large increases in patients prescribed and increases in the duration of treatment, but latterly more by increases in duration of treatment and the mean dose prescribed. However, patterns of change varied considerably by class of drugs, indicating that simple targets to reduce antidepressant prescribing are unlikely to be effective.
British Journal of General Practice, September 2011 e566 'other' antidepressants). Total DDDs, mean DDDs per patient, mean duration of treatment per patient, and mean DDDs per 28 days per patient were calculated for all antidepressants and the three main drug classes. Change over time was assessed using χ 2 tests for proportions, and one-way analysis of variance with Tukey post hoc tests for continuous variables. However, given the size of the dataset, virtually any comparison is likely to be statistically significant, and the magnitude of differences should be carefully considered for clinical significance.
The project used fully anonymised data with Caldicott Guardian approval according to the HIC Standard Operating Procedures, and NHS research ethics committee approval was therefore not required. All analysis was conducted using SPSS (version 17.0). (Table 2 ). Large increases in the numbers of patients prescribed occurred in patients aged ≥35 years, with the greatest increase occurring in the ≥85 years age group (6.7%). Prescribing rose more modestly in younger patients, with a 2.0% increase in the 16-24 years age group. Prescribing increased for both women and men, with a larger rise in women, who remained twice as likely as men to receive an antidepressant. There was no consistent gradient of either antidepressant use, or increases in antidepressant use by socioeconomic status measured by the postcode-assigned Scottish Index of Multiple Deprivation (SIMD). 19 The largest increase in prescribing by deprivation category was observed in the second-least deprived population quintile (SIMD 2 ), with the second highest rise noted in the most deprived quintile (SIMD 5 ). Those in SIMD 4 remained the least likely to be prescribed an antidepressant, and prescribing in this sector rose by only 2.3% (95% confidence interval [CI] = 2.1 to 2.5). Tables 3 and 4 show changes in the percentage of patients prescribed each of the three main drug classes, and dominated tricyclic prescribing, with falls in the use of all other drugs, with the exception of trazodone which modestly increased ( Table 5 ). The drugs included in the 'other antidepressant' category were prescribed to only 584 (0.2%) patients in 1995/1996, but to 6117 (1.9%) patients 10 years later. Mirtazapine was the most commonly prescribed drug in 2006/2007, although the halting of the rise in venlafaxine prescription is likely to be associated with the (temporary) shift of its status to specialist only prescribing, and may not have been sustained (Table 5) .
RESULTS

The
Age-sex-standardised rates generally mirror crude rates, indicating that the changing population structure has had little influence on prescribing patterns. Both SSRIs and 'other antidepressants' are prescribed to similar proportions of each age group, but TCADs are more commonly prescribed in middle-aged and older people. Prescribing by sex and socioeconomic status for each drug class mirrors the overall pattern, with the exception of proportionally higher prescribing of 'other antidepressants' observed in males and high social deprivation in the latter time frame, and a decrease in prescribing of TCADs in the two e569 British Journal of General Practice, September 2011 ) also received at least one prescription for a different SSRI, 1053 (11.4%) for a tricyclic and related drug, 610 (6.6%) for an 'other' antidepressant, and six (0.1%) for an MAOI. Table 6 shows how total drug volume, number of patients prescribed, mean days' treatment per patient, and mean dose per patient per 28 days' treatment changed over 
DISCUSSION
Summary
This study found that total antidepressant DDDs dispensed more than tripled between 1995/1996 and 2005/2006, due to a mixture of more patients being prescribed higher mean doses of drugs for longer. The contribution of these three factors varied depending on the drug class and time period examined, and between different drugs in the same class. Increased prescribing was experienced by all age groups, men and women, and all socioeconomic groups (although increases were smaller for younger people, men, and the most affluent). SSRI prescribing showed a similar pattern to total prescribing, but with shifts away from older drugs like paroxetine and sertraline to citalopram and escitalopram. TCAD prescribing was relatively static in terms of numbers of patients treated, with only small changes in treatment duration and mean dose, but there was a marked shift to increasing use of amitriptyline. In contrast, there were very large increases in 'other antidepressant' prescribing, driven by large rises in the number of patients prescribed across the whole period, and, latterly particularly, by increases in treatment length.
Strengths and limitations
A key strength of this study is that the analysis is based on patient-level dispensed prescribing data for an entire regional population, rather than practice-level data on total drug volume. [2] [3] [4] 7, 10 A weakness is the lack of clinical data on indication for prescribing.
Comparison with existing literature Notably, the results of this study differ from those of the study by Moore et al, of antidepressant prescribing for those with first-ever depression. 17 That study concluded that there had been little change in diagnosis or antidepressant initiation, and that rising antidepressant volumes were largely driven by more patients being prescribed antidepressants long term. 21 There was some evidence of increasing long-term use in the present study. However, the present study also found that the proportion of patients treated increased significantly over 10 years, as did mean doses used. An explanation for the difference is that antidepressants have a range of uses beyond depression, with these uses increasingly promoted by both clinical guidelines (for example for irritable bowel syndrome 22 ) and the pharmaceutical industry. 15 Analysing overall patterns of prescribing is therefore complementary to analyses by indication.
Implications for practice and research Policy and guidance on antidepressant prescribing has sometimes seemed contradictory. Recent policy has promoted blanket reductions in total prescribing volume because of assumed overuse, 10 depression, and promoted more prolonged use of antidepressants. 2, 3, 21 There clearly have been large increases in the number of people prescribed SSRIs and 'other' antidepressants like venlafaxine, mirtazapine, and duloxetine. However, the increase in drug volume has also been significantly driven by longer durations of treatment and increasing average doses, which are at least partly consistent with guideline-recommended management. 11, 13 The present study cannot directly examine this because no data are available on indication, but this interpretation is supported by the study of Moore et al. 17 In contrast, TCAD prescribing was essentially static in volume (although it still accounted for ~20% of antidepressant volume in 2006/2007), and increasingly consisted of low-dose amitriptyline. This is consistent with TCADs being used for a range of largely un-licensed but sometimes guidelinerecommended indications, such as chronic pain, fibromyalgia, irritable bowel syndrome, and anxiety, psychological distress, and night sedation (at least partly to avoid the use of benzodiazepines, which prescribing-improvement activity has often focused on reducing). 18, 22, 23 Of concern is the increasing use of TCADs in older people, in whom the risk of anticholinergic side effects, including falls and cognitive impairment, is greatest. 24 The key policy implication is that improving the quality of antidepressant prescribing will require a more multifaceted approach than simply focusing either on total antidepressant volume (because the factors driving changes vary by drug class) or the management of depression (since all antidepressants are used for a range of indications, and TCADs seem likely to be predominately used for other indications).
There are several areas where further research would be beneficial. First, it is important to better understand when and why patients are prescribed antidepressants for conditions other than depression, and to create better evidence of effectiveness of antidepressants in these other conditions. Secondly, there is relatively little evidence for the effectiveness of long-term antidepressant treatment in people with depression in primary care. 21 Although there is justified concern about lack of review for this group of patients, 17 there is relatively little evidence as to the likely prognosis if antidepressants are continued or stopped. Thirdly, it would be useful to better understand why and how new and more expensive drugs with little clear benefit over older drugs become established in local prescribing cultures. Finally, there is a need for the routine monitoring of antidepressant prescribing at patient level, rather than solely measuring drug volume. This should be feasible, given that almost all primary care prescribing is now done on computer and therefore recorded in a retrievable form, and particularly once true electronic prescribing is fully implemented.
